Brickell Biotech

$0.6872
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0076 (+1.12%) As of 6:23 PM UTC today

Why Robinhood?

You can buy or sell BBI and other stocks, options, and ETFs commission-free!

About BBI

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO. The listed name for BBI is Brickell Biotech, Inc. Common Stock.

CEO
Robert B. Brown
Employees
15
Headquarters
Boulder, Colorado
Founded
2009
Market Cap
36.79M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.24M
High Today
$0.71
Low Today
$0.6801
Open Price
$0.69
Volume
1.99M
52 Week High
$3.98
52 Week Low
$0.466

Collections

BBI Earnings

-$2.44
-$1.63
-$0.81
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 17, After Hours

You May Also Like